Healthcare
Live Price
Offline$0.8368
+0.00% today
1Y Change
-26.32%
Window
Jun 26, 2025 → Jun 19, 2026
Coverage: 252 bars · Jun 26, 2025 → Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is a Healthcare stock with a market cap of $16.17B and listed on OTC. The stock last traded around $0.84 and down 26.3% across the available one-year price window (Jun 26, 2025 → Jun 19, 2026). Baseline metrics include revenue growth of +9.0%, EPS growth of -94.0%, a dividend yield of 4.8%. What stands out right now is revenue +9.0%, EPS -94.0%, free cash flow -51.7% with operating margin 21.2% and ROIC 14.4%. The dividend matters to the case here, with a current yield around 4.8%. Valuation is more restrained than many high-expectation growth names at P/E 9.7 and price/sales 0.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines GNMLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GNMLF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GNMLF Max Drawdown
-28.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for GNMLF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$754.1M
-12.6% YoY
FY Net Income
$63.7M
-10.6% YoY
Free Cash Flow
$13.5M
-78.7% YoY
Revenue Growth
+9.0%
EPS Growth
-94.0%
Gross Margin
62.7%
Net Margin
9.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 973M | 892M | 969M | 862M | 754M |
| Gross Profit | 611M | 572M | 594M | 521M | 466M |
| Operating Income | 207M | 188M | 189M | 169M | 146M |
| EBITDA | 228M | 4.1B | 167M | 153M | 143M |
| Net Income | 89M | 1.5B | 64M | 71M | 64M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 159M | 2.4B | 1.5B | 77M | 62M |
| Total Assets | 1.3B | 1.1B | 1.2B | 1.1B | 1.0B |
| Total Liabilities | 706M | 582M | 664M | 587M | 559M |
| Shareholder Equity | 616M | 11.6B | 552M | 521M | 490M |
| Total Debt | 425M | 311M | 6.2B | 330M | 290M |
| Net Debt | 266M | 4.2B | 4.8B | 253M | 229M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
-36.4% YoY
Capital Expenditures
41M
-88.1% YoY
Free Cash Flow
14M
-78.7% YoY
Key ratios
Gross Margin
62.7%
Operating Margin
21.2%
Net Margin
9.6%
ROE
14.8%
Debt / Equity
0.40x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.